BRCA2 and cancer: Hence, inactivation of HR makes cells very sensitive to ICL adducts, and cancers defective in HR (for example, those with BRCA1 or BRCA2 mutations) are good targets for treatment with cisplatin or mitomycin C. HR, as an important part of meiosis, is also very important for the generation of germ cells.